These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25515836)

  • 1. Sodium channel slow inactivation as a therapeutic target for myotonia congenita.
    Novak KR; Norman J; Mitchell JR; Pinter MJ; Rich MM
    Ann Neurol; 2015 Feb; 77(2):320-32. PubMed ID: 25515836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting persistent inward sodium currents prevents myotonia.
    Hawash AA; Voss AA; Rich MM
    Ann Neurol; 2017 Sep; 82(3):385-395. PubMed ID: 28833464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism underlying transient weakness in myotonia congenita.
    Myers JH; Denman K; DuPont C; Hawash AA; Novak KR; Koesters A; Grabner M; Dayal A; Voss AA; Rich MM
    Elife; 2021 Apr; 10():. PubMed ID: 33904400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of myotonia congenita with retigabine in mice.
    Dupont C; Denman KS; Hawash AA; Voss AA; Rich MM
    Exp Neurol; 2019 May; 315():52-59. PubMed ID: 30738808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines on clinical presentation and management of nondystrophic myotonias.
    Stunnenberg BC; LoRusso S; Arnold WD; Barohn RJ; Cannon SC; Fontaine B; Griggs RC; Hanna MG; Matthews E; Meola G; Sansone VA; Trivedi JR; van Engelen BGM; Vicart S; Statland JM
    Muscle Nerve; 2020 Oct; 62(4):430-444. PubMed ID: 32270509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
    Desaphy JF; Carbonara R; Costanza T; Conte Camerino D
    Exp Neurol; 2014 May; 255(100):96-102. PubMed ID: 24613829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plateau potentials contribute to myotonia in mouse models of myotonia congenita.
    Wang X; Dupont C; Grant D; Voss AA; Rich MM
    Exp Neurol; 2023 Mar; 361():114303. PubMed ID: 36563835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants.
    El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S
    Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita.
    Ginanneschi F; Mignarri A; Lucchiari S; Ulzi G; Comi GP; Rossi A; Dotti MT
    Neurophysiol Clin; 2017 Jun; 47(3):247-252. PubMed ID: 28153715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacological in vitro investigations on low chloride conductance myotonia: effects of potassium regulation.
    Hoppe K; Chaiklieng S; Lehmann-Horn F; Jurkat-Rott K; Wearing S; Klingler W
    Pflugers Arch; 2020 Oct; 472(10):1481-1494. PubMed ID: 32748018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label trial of ranolazine for the treatment of myotonia congenita.
    Arnold WD; Kline D; Sanderson A; Hawash AA; Bartlett A; Novak KR; Rich MM; Kissel JT
    Neurology; 2017 Aug; 89(7):710-713. PubMed ID: 28710329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.
    Lo Monaco M; D'Amico A; Luigetti M; Desaphy JF; Modoni A
    Clin Neurophysiol; 2015 Feb; 126(2):399-403. PubMed ID: 25065301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myotonia congenita.
    Lossin C; George AL
    Adv Genet; 2008; 63():25-55. PubMed ID: 19185184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional consequences of chloride channel gene (CLCN1) mutations causing myotonia congenita.
    Zhang J; Bendahhou S; Sanguinetti MC; Ptácek LJ
    Neurology; 2000 Feb; 54(4):937-42. PubMed ID: 10690989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label trial of ranolazine for the treatment of paramyotonia congenita.
    Lorusso S; Kline D; Bartlett A; Freimer M; Agriesti J; Hawash AA; Rich MM; Kissel JT; David Arnold W
    Muscle Nerve; 2019 Feb; 59(2):240-243. PubMed ID: 30390395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloride channels in myotonia congenita assessed by velocity recovery cycles.
    Tan SV; Z'Graggen WJ; Boërio D; Rayan DR; Norwood F; Ruddy D; Howard R; Hanna MG; Bostock H
    Muscle Nerve; 2014 Jun; 49(6):845-57. PubMed ID: 24037712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic variability in myotonia congenita.
    Colding-Jørgensen E
    Muscle Nerve; 2005 Jul; 32(1):19-34. PubMed ID: 15786415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of extracellular osmolarity improves signs of myotonia congenita in vitro: a preclinical animal study.
    Hoppe K; Chaiklieng S; Lehmann-Horn F; Jurkat-Rott K; Wearing S; Klingler W
    J Physiol; 2019 Jan; 597(1):225-235. PubMed ID: 30284249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo.
    Desaphy JF; Farinato A; Altamura C; De Bellis M; Imbrici P; Tarantino N; Caccia C; Melloni E; Padoani G; Vailati S; Keywood C; Carratù MR; De Luca A; Conte D; Pierno S
    Exp Neurol; 2020 Jun; 328():113287. PubMed ID: 32205118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel murine myotonia congenita without molecular defects in the ClC-1 and the SCN4A.
    Shirakawa T; Sakai K; Kitagawa Y; Hori A; Hirose G
    Neurology; 2002 Oct; 59(7):1091-4. PubMed ID: 12370472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.